QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:PTCT

PTC Therapeutics News Headlines

$53.89
+1.42 (+2.71 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$51.24
Now: $53.89
$54.27
50-Day Range
$45.41
MA: $49.53
$54.60
52-Week Range
$30.79
Now: $53.89
$59.89
Volume351,660 shs
Average Volume760,533 shs
Market Capitalization$3.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08

Headlines

PTC Therapeutics (NASDAQ PTCT) News Headlines Today

Source:
SourceHeadline
PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at UBS GroupPTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at UBS Group
marketbeat.com - October 28 at 7:48 AM
Raymond James Reaffirms Buy Rating for PTC Therapeutics (NASDAQ:PTCT)Raymond James Reaffirms Buy Rating for PTC Therapeutics (NASDAQ:PTCT)
marketbeat.com - September 23 at 6:18 PM
PTC Therapeutics, Inc.to Host Earnings CallPTC Therapeutics, Inc.to Host Earnings Call
finance.yahoo.com - October 29 at 2:46 PM
PTC Therapeutics Q3 Earnings PreviewPTC Therapeutics Q3 Earnings Preview
seekingalpha.com - October 28 at 5:27 PM
PTC Therapeutics to Participate at Upcoming Virtual Investor ConferencesPTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
finance.yahoo.com - October 28 at 12:26 PM
PTC Therapeutics (NASDAQ:PTCT) Research Coverage Started at UBS GroupPTC Therapeutics (NASDAQ:PTCT) Research Coverage Started at UBS Group
americanbankingnews.com - October 28 at 10:02 AM
Atreca (NASDAQ:BCEL) and PTC Therapeutics (NASDAQ:PTCT) Critical SurveyAtreca (NASDAQ:BCEL) and PTC Therapeutics (NASDAQ:PTCT) Critical Survey
americanbankingnews.com - October 27 at 9:43 AM
PTC launches study of vatiquinone for mitochondrial epilepsyPTC launches study of vatiquinone for mitochondrial epilepsy
seekingalpha.com - October 26 at 12:49 PM
PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial EpilepsyPTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy
finance.yahoo.com - October 26 at 12:49 PM
PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in MassachusettsPTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts
finance.yahoo.com - October 22 at 11:09 AM
PTC Therapeuticss Evrysdi Okd in Brazil for spinal muscular atrophyPTC Therapeutics's Evrysdi Ok'd in Brazil for spinal muscular atrophy
seekingalpha.com - October 21 at 12:32 PM
PTC Therapeutics Evrysdi OKd in Brazil for spinal muscular atrophyPTC Therapeutics' Evrysdi OK'd in Brazil for spinal muscular atrophy
seekingalpha.com - October 21 at 12:32 PM
Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular AtrophyEvrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy
finance.yahoo.com - October 21 at 12:32 PM
PTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 5,000 SharesPTC Therapeutics, Inc. (NASDAQ:PTCT) Director Allan Steven Jacobson Sells 5,000 Shares
americanbankingnews.com - October 20 at 6:11 PM
Is Therapeutics (NASDAQ:PTCT) Using Debt In A Risky Way?Is Therapeutics (NASDAQ:PTCT) Using Debt In A Risky Way?
finance.yahoo.com - October 20 at 2:53 PM
PTC THERAPEUTICS DL-,001 (P91.MU)PTC THERAPEUTICS DL-,001 (P91.MU)
au.finance.yahoo.com - October 13 at 3:35 PM
Christine Marie Utter Sells 2,500 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) StockChristine Marie Utter Sells 2,500 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock
americanbankingnews.com - October 8 at 12:32 AM
PTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $6,232,472.12 in StockPTC Therapeutics, Inc. (NASDAQ:PTCT) CEO Sells $6,232,472.12 in Stock
americanbankingnews.com - October 8 at 12:32 AM
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $49.64PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up to $49.64
americanbankingnews.com - October 7 at 11:43 AM
PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Overweight at JPMorgan Chase & Co.PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Overweight at JPMorgan Chase & Co.
americanbankingnews.com - October 7 at 7:22 AM
Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental MilestonesTwo-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
finance.yahoo.com - September 28 at 7:18 PM
Roche and PTCs risdiplam shows durable effect in infants with spinal muscular atrophyRoche and PTC's risdiplam shows durable effect in infants with spinal muscular atrophy
seekingalpha.com - September 28 at 9:17 AM
PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing SummitPTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit
finance.yahoo.com - September 24 at 9:10 AM
Hedge Funds Are Dipping Their Toes Back Into PTC Therapeutics, Inc. (PTCT)Hedge Funds Are Dipping Their Toes Back Into PTC Therapeutics, Inc. (PTCT)
finance.yahoo.com - September 15 at 11:15 AM
Should You Take Comfort From Insider Transactions At PTC Therapeutics, Inc. (NASDAQ:PTCT)?Should You Take Comfort From Insider Transactions At PTC Therapeutics, Inc. (NASDAQ:PTCT)?
finance.yahoo.com - September 14 at 7:31 PM
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter DisordersPTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders
finance.yahoo.com - September 9 at 8:33 AM
PTC Therapeutics 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy OrganizationsPTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
prnewswire.com - September 8 at 12:30 PM
PTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy OrganizationsPTC Therapeutics' 2020 STRIVE Awards for Duchenne Muscular Dystrophy Recognize Four Patient Advocacy Organizations
finance.yahoo.com - September 8 at 12:30 PM
PTC Therapeutics to Present at the Cantor Virtual Global Healthcare ConferencePTC Therapeutics to Present at the Cantor Virtual Global Healthcare Conference
finance.yahoo.com - September 3 at 8:58 AM
PTC Therapeutics Gets First Milestone Payment for SMA DrugPTC Therapeutics Gets First Milestone Payment for SMA Drug
nasdaq.com - August 27 at 11:01 AM
PTC Therapeutics earns $20M milestone from Roche on sale of risdiplam in U.S.PTC Therapeutics earns $20M milestone from Roche on sale of risdiplam in U.S.
seekingalpha.com - August 26 at 9:27 AM
PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)PTC Therapeutics Announces First Commercial Milestone Payment Following U.S. FDA Approval of Evrysdi™ (risdiplam)
finance.yahoo.com - August 26 at 9:27 AM
PTC Therapeutics Application for SMA Drug Accepted by EUPTC Therapeutics' Application for SMA Drug Accepted by EU
nasdaq.com - August 18 at 5:56 PM
PTC Therapeutics' Application for SMA Drug Accepted by EUPTC Therapeutics' Application for SMA Drug Accepted by EU
finance.yahoo.com - August 18 at 5:56 PM
PTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular AtrophyPTC Announces the Acceptance of the European Marketing Authorization Application for Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy
finance.yahoo.com - August 17 at 8:24 AM
PTC Therapeutics Scores Early FDA Nod For Evrysdi; Analyst Stays SidelinedPTC Therapeutics Scores Early FDA Nod For Evrysdi; Analyst Stays Sidelined
finance.yahoo.com - August 10 at 1:45 PM
FDA OKs PTC Therapeutics spinal muscular atrophy treatment EvrysdiFDA OKs PTC Therapeutics' spinal muscular atrophy treatment Evrysdi
seekingalpha.com - August 7 at 6:10 PM
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Path To ProfitabilityPTC Therapeutics, Inc.'s (NASDAQ:PTCT) Path To Profitability
finance.yahoo.com - August 7 at 6:10 PM
PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE MagazinePTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
finance.yahoo.com - August 6 at 9:51 AM
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2020 Results - Earnings Call TranscriptPTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com - August 5 at 11:50 PM
PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue EstimatesPTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 5 at 11:50 PM
PTC Therapeutics EPS misses by $1.48, misses on revenuePTC Therapeutics EPS misses by $1.48, misses on revenue
seekingalpha.com - August 5 at 6:49 PM
PTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate UpdatePTC Therapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - August 5 at 6:49 PM
PTC Therapeutics Q2 2020 Earnings PreviewPTC Therapeutics Q2 2020 Earnings Preview
seekingalpha.com - August 4 at 8:25 PM
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Should You Buy?
finance.yahoo.com - July 29 at 1:15 PM
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial ResultsPTC Therapeutics to Host Conference Call to Discuss Second Quarter 2020 Financial Results
finance.yahoo.com - July 22 at 10:04 AM
PTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 MillionPTC Therapeutics Announces Agreement to Monetize a Portion of the Risdiplam Royalty Stream for $650 Million
www.prnewswire.com - July 20 at 12:14 PM
Did Hedge Funds Make The Right Call On PTC Therapeutics, Inc. (PTCT)Did Hedge Funds Make The Right Call On PTC Therapeutics, Inc. (PTCT)
finance.yahoo.com - July 13 at 12:55 AM
PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857PTC Therapeutics Announces First Patient Dosed in Phase 1 Trial for PTC857
finance.yahoo.com - July 8 at 8:30 AM
PTC Therapeutics Announces CHMP Recommendation of Translarna (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular DystrophyPTC Therapeutics Announces CHMP Recommendation of Translarna (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
www.finanznachrichten.de - June 29 at 11:32 AM
European advisory group backs labeling change for PTC Therapeutics TranslarnaEuropean advisory group backs labeling change for PTC Therapeutics' Translarna
seekingalpha.com - June 29 at 11:32 AM
PTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular DystrophyPTC Therapeutics Announces CHMP Recommendation of Translarna™ (ataluren) Label Update for Non-Ambulatory Patients with Duchenne Muscular Dystrophy
finance.yahoo.com - June 29 at 11:32 AM
This page was last updated on 10/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.